Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
w decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 we » _ we (Expand Search), 5 wt (Expand Search), 5 e (Expand Search)
5 w » 5 wt (Expand Search)
Showing 61 - 80 results of 66,116 for search '(((( 5 we decrease ) OR ( 5 w decrease ))) OR ( 5 ((mean decrease) OR (a decrease)) ))', query time: 1.19s Refine Results
  1. 61
    Frequency distribution of the hourly ERA5 reanalysis vs observations illustrating the best score (a: W02 station and b: W11 station) and the poorest score (c: W18 station and b: W19 station).

    Frequency distribution of the hourly ERA5 reanalysis vs observations illustrating the best score (a: W02 station and b: W11 station) and the poorest score (c: W18 station and b: W1... by Weidong Ji (129916)

    Published 2025
    Save to List
    Saved in:
  2. 62
    Image5_Orally Administered Probiotics Decrease Aggregatibacter actinomycetemcomitans but Not Other Periodontal Pathogenic Bacteria Counts in the Oral Cavity: A Systematic Review and Meta-Analysis.TIF

    Image5_Orally Administered Probiotics Decrease Aggregatibacter actinomycetemcomitans but Not Other Periodontal Pathogenic Bacteria Counts in the Oral Cavity: A Systematic Review and Meta-Analysis.TIF by Thanyaporn Sang-Ngoen (11241888)

    Published 2021
    Save to List
    Saved in:
  3. 63
    Table5_Orally Administered Probiotics Decrease Aggregatibacter actinomycetemcomitans but Not Other Periodontal Pathogenic Bacteria Counts in the Oral Cavity: A Systematic Review and Meta-Analysis.DOCX

    Table5_Orally Administered Probiotics Decrease Aggregatibacter actinomycetemcomitans but Not Other Periodontal Pathogenic Bacteria Counts in the Oral Cavity: A Systematic Review and Meta-Analysis.DOCX by Thanyaporn Sang-Ngoen (11241888)

    Published 2021
    Save to List
    Saved in:
  4. 64
    Table5_Orally Administered Probiotics Decrease Aggregatibacter actinomycetemcomitans but Not Other Periodontal Pathogenic Bacteria Counts in the Oral Cavity: A Systematic Review and Meta-Analysis.DOCX

    Table5_Orally Administered Probiotics Decrease Aggregatibacter actinomycetemcomitans but Not Other Periodontal Pathogenic Bacteria Counts in the Oral Cavity: A Systematic Review and Meta-Analysis.DOCX by Thanyaporn Sang-Ngoen (11241888)

    Published 2021
    Save to List
    Saved in:
  5. 65
    Image5_Orally Administered Probiotics Decrease Aggregatibacter actinomycetemcomitans but Not Other Periodontal Pathogenic Bacteria Counts in the Oral Cavity: A Systematic Review and Meta-Analysis.TIF

    Image5_Orally Administered Probiotics Decrease Aggregatibacter actinomycetemcomitans but Not Other Periodontal Pathogenic Bacteria Counts in the Oral Cavity: A Systematic Review and Meta-Analysis.TIF by Thanyaporn Sang-Ngoen (11241888)

    Published 2021
    Save to List
    Saved in:
  6. 66
    TREM1 inhibition decreases HIV mediated inflammatory cytokine production.

    TREM1 inhibition decreases HIV mediated inflammatory cytokine production. by Jinhee Hyun (6900683)

    Published 2019
    Save to List
    Saved in:
  7. 67
    Decreased vagal activity and deviation in sympathetic activity precedes development of diabetes

    Decreased vagal activity and deviation in sympathetic activity precedes development of diabetes by Da Young Lee (8617365)

    Published 2020
    Save to List
    Saved in:
  8. 68
    S5 Fig -

    S5 Fig - by Jordan K. Abbott (8934239)

    Published 2022
    Save to List
    Saved in:
  9. 69
    The spectral sensitivity of European seabass fed a 5% taurine diet.

    The spectral sensitivity of European seabass fed a 5% taurine diet. by Richard W. Brill (2337940)

    Published 2019
    Save to List
    Saved in:
  10. 70
    MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG.

    MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

    Published 2024
    Save to List
    Saved in:
  11. 71
    Decreased respiratory performance of children and adolescents with myelomeningocele who use a wheelchair – preliminary data

    Decreased respiratory performance of children and adolescents with myelomeningocele who use a wheelchair – preliminary data by E.J. Martins (7141313)

    Published 2019
    Save to List
    Saved in:
  12. 72
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 73
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 74
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 75
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 76
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 77
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 78
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 79
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 80
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: